0000000000336550

AUTHOR

Nadia Aissaoui

showing 6 related works from this author

Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)

2017

IF 3.398; International audience; The prognosis of patients with acute myocardial infarction (AMI) has notably improved in the past 20 years. Using the French Registry of ST-Elevation and Non-ST-elevation Myocardial Infarction (FAST-MI) 2010 registry, we investigated whether previous manifestations of atherosclerotic disease (i.e., previous MI, or a history of any form of atherosclerotic disease) are at truly increased risk compared with those in whom AMI is the first manifestation of the disease. FAST-MI 2010 is a nationwide French registry including 3,079 patients with AMI, among whom 1,062 patients had a history of cardiovascular atherosclerotic disease and 498 patients had a history of …

MaleMESH : Atherosclerosismedicine.medical_treatmentMESH : MortalityMyocardial InfarctionMESH : AgedMESH : Prospective StudiesAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDiseaseMESH : Cerebrovascular Disorders0302 clinical medicineMedicineLongitudinal StudiesProspective StudiesMESH: Coronary Artery DiseaseMyocardial infarctionCoronary Artery BypassMESH: Treatment OutcomeCause of deathAged 80 and overeducation.field_of_studyMESH: Middle AgedHazard ratioMESH : Platelet Aggregation InhibitorsPrognosisMESH: Case-Control Studies3. Good healthMESH: Myocardial InfarctionMESH: Angiotensin Receptor AntagonistsMESH : Angiotensin-Converting Enzyme InhibitorsCardiology and Cardiovascular MedicineMESH: Percutaneous Coronary InterventionMESH : Case-Control Studiesmedicine.medical_specialtyMESH : Angiotensin Receptor AntagonistsMESH: Prognosis03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedMESH : Coronary Artery DiseaseMESH : Aged 80 and overMESH: Hydroxymethylglutaryl-CoA Reductase InhibitorseducationMESH: Age DistributionAgedMESH: HumansMESH: MortalityProportional hazards modelMESH: Coronary Artery BypassMESH : HumansCase-control studyMESH : Proportional Hazards Modelsmedicine.diseaseMESH : Coronary Artery BypassCase-Control StudiesMESH: FemaleMESH: RegistriesMESH : Age Distribution030204 cardiovascular system & hematologyMESH: AtherosclerosisMESH: Proportional Hazards ModelsMESH: Cause of DeathMESH: Aged 80 and overMESH : Percutaneous Coronary InterventionRisk FactorsMESH: Risk FactorsCause of DeathMESH : FemaleRegistries030212 general & internal medicineMESH: Longitudinal StudiesMESH : Longitudinal StudiesMESH: AgedMESH : PrognosisMESH: Angiotensin-Converting Enzyme InhibitorsMESH: Adrenergic beta-AntagonistsMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsTreatment OutcomeMESH: Platelet Aggregation InhibitorsCardiologyFemaleMESH: Cerebrovascular DisordersFranceMESH : MaleAdrenergic beta-AntagonistsMESH : Adrenergic beta-AntagonistsPopulationMESH : Treatment OutcomeMESH: Multivariate AnalysisAngiotensin Receptor AntagonistsAge DistributionInternal medicineMortalityMESH : FranceProportional Hazards ModelsMESH : Cause of Deathbusiness.industryMESH : Hydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Multivariate AnalysisPercutaneous coronary interventionAtherosclerosisMESH: MaleMESH: Prospective StudiesMESH: FranceCerebrovascular DisordersMultivariate AnalysisHydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Myocardial InfarctionbusinessPlatelet Aggregation InhibitorsMESH : RegistriesThe American Journal of Cardiology
researchProduct

Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, ra…

2021

International audience; BACKGROUND: Delaying renal replacement therapy (RRT) for some time in critically ill patients with severe acute kidney injury and no severe complication is safe and allows optimisation of the use of medical devices. Major uncertainty remains concerning the duration for which RRT can be postponed without risk. Our aim was to test the hypothesis that a more-delayed initiation strategy would result in more RRT-free days, compared with a delayed strategy. METHODS: This was an unmasked, multicentre, prospective, open-label, randomised, controlled trial done in 39 intensive care units in France. We monitored critically ill patients with severe acute kidney injury (defined …

medicine.medical_specialtyMESH: Acute Kidney Injury[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulation030204 cardiovascular system & hematologyurologic and male genital diseasesMESH: Severity of Illnes Index03 medical and health sciencesMESH: Aged 80 and over0302 clinical medicineOliguriaIntensive careInternal medicineMedicineMESH: Time-to-Treatment030212 general & internal medicineRenal replacement therapyeducationBlood urea nitrogenMESH: Agededucation.field_of_studyMESH: HumansMESH: Middle Agedbusiness.industryHazard ratioAcute kidney injuryGeneral Medicinemedicine.diseaseMESH: MaleMESH: Prospective Studies3. Good health[SDV] Life Sciences [q-bio]MESH: FranceMESH: Intensive Care Unitsmedicine.symptomMESH: Renal Remplacement TherapybusinessMESH: FemaleKidney diseaseThe Lancet
researchProduct

Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: a multicentre series of 52 cases

2018

International audience; Aims The role of extracorporeal membrane oxygenation (ECMO) remains ill defined in pulmonary embolism (PE). We investigated outcomes in patients with high-risk PE undergoing ECMO according to initial therapeutic strategy. Methods and results From 01 January 2014 to 31 December 2015, 180 patients from 13 Departments in nine centres with high-risk PE were retrospectively included. Among those undergoing ECMO, we compared characteristics and outcomes according to adjunctive treatment strategy (systemic thrombolysis, surgical embolectomy, or no reperfusion therapy). Primary outcome was all-cause 30-day mortality. Secondary outcome was 90-day major bleeding. One hundred a…

Malemedicine.medical_specialtymedicine.medical_treatment[SDV]Life Sciences [q-bio]Embolectomy030204 cardiovascular system & hematologyEmbolectomy03 medical and health sciences0302 clinical medicineReperfusion therapyExtracorporeal Membrane OxygenationFibrinolysismedicineExtracorporeal membrane oxygenationHumans030212 general & internal medicineRetrospective Studiesbusiness.industryRetrospective cohort studyThrombolysisMiddle Agedmedicine.diseasePrognosisPulmonary embolismSurgerySurvival Rate[SDV] Life Sciences [q-bio]surgical procedures operativeEchocardiographyAdjunctive treatmentFemaleFranceCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismFollow-Up Studies
researchProduct

The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial

2019

Abstract Background The Artificial Kidney Initiation in Kidney Injury (AKIKI) trial showed that a delayed renal replacement therapy (RRT) strategy for severe acute kidney injury (AKI) in critically ill patients was safe and associated with major reduction in RRT initiation compared with an early strategy. The five criteria which mandated RRT initiation in the delayed arm were: severe hyperkalemia, severe acidosis, acute pulmonary edema due to fluid overload resulting in severe hypoxemia, serum urea concentration > 40 mmol/l and oliguria/anuria > 72 h. However, duration of anuria/oliguria and level of blood urea are still criteria open to debate. The objective of the study is to compar…

Time FactorsHyperkalemiamedicine.medical_treatment[SDV]Life Sciences [q-bio]Medicine (miscellaneous)030204 cardiovascular system & hematologyKidneyurologic and male genital diseases[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrologylaw.inventionTime-to-Treatment03 medical and health sciencesStudy Protocol0302 clinical medicineRandomized controlled triallawOliguriamedicineHumansMulticenter Studies as TopicPharmacology (medical)030212 general & internal medicineRenal replacement therapyProspective StudiesTreatment outcomeRandomized Controlled Trials as TopicMechanical ventilationlcsh:R5-920business.industryRenal replacement therapyAcute kidney injuryRecovery of FunctionInterim analysismedicine.diseasefemale genital diseases and pregnancy complications3. Good healthAcute kidney injuryCritical careAnesthesiaAnuria[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancemedicine.symptombusinesslcsh:Medicine (General)Kidneys Artificial
researchProduct

In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French regi…

2019

Summary Background Cancer and acute myocardial infarction (AMI) have important prognostic consequences. Treatment of some cancers may affect coronary artery disease, myocardial function and/or AMI management. Whether the early and long-term mortality of patients with AMI differ according to their history of cancer remains questionable. Aims To determine in-hospital outcomes and 5-year mortality following AMI according to patient history of cancer. Methods The FAST-MI registry is a nationwide French survey collecting data on characteristics, management and outcomes of 3670 consecutive patients admitted for AMI during October 2005. Results Overall, 246/3664 patients (6.7%) admitted for an AMI…

Malemedicine.medical_specialtyTime Factors[SDV]Life Sciences [q-bio]Infarctus du myocardeAcute myocardial infarction030204 cardiovascular system & hematologyMortalitéRisk AssessmentCoronary artery disease03 medical and health sciences0302 clinical medicineRisk FactorsNeoplasmsInternal medicineMortalité hospitalière.medicineHumansMedical historyHospital MortalityProspective StudiesRegistries030212 general & internal medicineMyocardial infarctioncardiovascular diseasesRisk factorMortalityNon-ST Elevated Myocardial InfarctionAgedCancerAged 80 and overbusiness.industryST elevationHazard ratioGeneral MedicineOdds ratioMiddle Agedmedicine.disease3. Good healthHospitalization[SDV] Life Sciences [q-bio]In-hospital mortalityTreatment OutcomeCohortST Elevation Myocardial InfarctionFemaleFranceCardiology and Cardiovascular Medicinebusiness
researchProduct

MOESM1 of The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial

2019

Additional file 1. Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Checklist: recommended items to address in a clinical trial protocol and related documents*.

behavioral disciplines and activities
researchProduct